Simona Treidler, MD
Neurology · Stony Brook, NYNPI 1376888008
Payments from drug & device makers
Across 90 payments — averaging $715.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$33K
- Novartis$15K
- PTC Therapeutics, Inc.$15K
- Tanabe Pharma America, Inc.$507
- Amylyx Pharmaceuticals, Inc.$271
- ITF Therapeutics LLC$183
- plus $647 from 11 others
What the payments were for
- Food & beverage$1,71899%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 19 | $32,900 |
| Novartis | 2 | $15,281 |
| PTC Therapeutics, Inc. | 5 | $14,580 |
| Tanabe Pharma America, Inc. | 22 | $507 |
| Amylyx Pharmaceuticals, Inc. | 13 | $271 |
| ITF Therapeutics LLC | 4 | $183 |
| Biogen | 6 | $147 |
| UCB, Inc. | 1 | $113 |
| NS Pharma, Inc. | 5 | $100 |
| Sanofi | 2 | $65 |
| Baxter Healthcare | 2 | $45 |
| Sarepta Therapeutics, Inc. | 2 | $43 |
| AstraZeneca(2 entities) | 2 | $39 |
| Genentech USA, Inc. | 2 | $35 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| CSL Behring | 1 | $20 |
| Pfizer | 1 | $18 |
How this compares
$64,369 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 142 | $1,910,657 |
| NexviazymeAvalglucosidase Alfa-Ngpt | 13 | $503,208 |
| EvrysdiRisdiplam | 16 | $420,379 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 71 | $378,727 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 20 | $373,479 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 29 | $366,584 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 14 | $281,010 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 15 | $271,713 |
| EmflazaDeflazacort | 17 | $148,397 |
| NuedextaDextromethorphan Hbr/Quinidine | 63 | $112,872 |
| Riluzole | 181 | $27,335 |
| Repatha SureclickEvolocumab | 20 | $13,412 |
| Pyridostigmine Bromide | 46 | $9,133 |
| Repatha SyringeEvolocumab | 22 | $8,428 |
| Praluent PenAlirocumab | 15 | $8,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiNexviazyme | $65 | $503,20813 claims |
| Genentech USA, Inc.Evrysdi | $35 | $420,37916 claims |
| CSL BehringPrivigen | $20 | $373,47920 claims |
| Amylyx Pharmaceuticals, Inc.Relyvrio | $271 | $366,58429 claims |
| PTC Therapeutics, Inc.Emflaza | $14,580 | $148,39717 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $22 | $112,87263 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.
Other neurology in Stony Brook
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
- Krupa PandeyAlbany$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.